Comparing SG&A Expenses: Johnson & Johnson vs Apellis Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

In the world of pharmaceuticals, the Selling, General, and Administrative (SG&A) expenses are a critical measure of a company's operational efficiency. Over the past decade, Johnson & Johnson and Apellis Pharmaceuticals, Inc. have shown contrasting trends in their SG&A expenses.

Johnson & Johnson: A Steady Giant

From 2014 to 2023, Johnson & Johnson's SG&A expenses have remained relatively stable, averaging around $21 billion annually. This consistency reflects the company's robust operational strategies and market dominance. However, a slight decline of about 5% was observed from 2018 to 2022, indicating potential cost optimization efforts.

Apellis Pharmaceuticals: A Rapid Climber

In contrast, Apellis Pharmaceuticals has seen a dramatic increase in SG&A expenses, skyrocketing from approximately $3 million in 2014 to over $500 million in 2023. This 170-fold increase underscores the company's aggressive expansion and investment in market penetration.

These trends highlight the diverse strategies employed by established giants and emerging players in the pharmaceutical industry.